Topical HPMC/S-Nitrosoglutathione Solution Decreases Inflammation and Bone Resorption in Experimental Periodontal Disease in Rats.
S-nitrosoglutathione (GSNO) is a nitric oxide (NO) donor, which exerts antioxidant, anti-inflammatory, and microbicidal actions. Intragingival application of GSNO was already shown to decrease alveolar bone loss, inflammation and oxidative stress in an experimental periodontal disease (EPD) model. In the present study, we evaluated the potential therapeutic effect of topical applications of hydroxypropylmethylcellulose (HPMC)/GSNO solutions on EPD in Wistar rats. EPD was induced by placing a sterilized nylon (3.0) thread ligature around the cervix of the second left upper molar of the animals, which received topical applications of a HPMC solutions containing GSNO 2 or 10 mM or vehicle (HPMC solution), 1 h prior to the placement of the ligature and then twice daily until sacrifice on day 11. Treatment with HPMC/GSNO 10 mM solution significantly reduced alveolar bone loss, oxidative stress and TNF-α e IL-1β levels in the surrounding gingival tissue, and led to a decreased transcription of RANK and TNF-α genes and elevated bone alkaline phosphatase, compared to the HPMC group. In conclusion, topical application of HPMC/GSNO solution is a potential treatment to reduce inflammation and bone loss in periodontal disease.
Postgraduate Program in Morphofunctional Sciences, Department of Morphology, School of Medicine, Federal University of Ceará, Fortaleza, Ceará, Brazil.
Conceição S
CS
Martins
Postgraduate Program in Morphofunctional Sciences, Department of Morphology, School of Medicine, Federal University of Ceará, Fortaleza, Ceará, Brazil.
Renata F C
RF
Leitão
Postgraduate Program in Morphofunctional Sciences, Department of Morphology, School of Medicine, Federal University of Ceará, Fortaleza, Ceará, Brazil.
Deiziane V S
DV
Costa
Department of Clinical Dentistry, Faculty of Pharmacy, Dentistry and Nursing, School of Dentistry. Federal University of Ceará, Fortaleza, Ceará, Brazil.
Iracema M
IM
Melo
Postgraduate Program in Morphofunctional Sciences, Department of Morphology, School of Medicine, Federal University of Ceará, Fortaleza, Ceará, Brazil.
Glaylton S
GS
Santos
Department of Physiology and Pharmacology, School of Medicine, Federal University of Ceará, Fortaleza, Ceará, Brazil.
Vilma
V
Lima
Institute of Chemistry, University of Campinas, UNICAMP, Campinas, São Paulo, Brazil.
Victor
V
Baldim
Department of Physiology and Pharmacology, School of Medicine, Federal University of Ceará, Fortaleza, Ceará, Brazil.
Deysi V T
DV
Wong
Postgraduate Program in Morphofunctional Sciences, Department of Morphology, School of Medicine, Federal University of Ceará, Fortaleza, Ceará, Brazil.
Luana E
LE
Bonfim
Postgraduate Program in Morphofunctional Sciences, Department of Morphology, School of Medicine, Federal University of Ceará, Fortaleza, Ceará, Brazil.
Cíntia B
CB
Melo
Institute of Chemistry, University of Campinas, UNICAMP, Campinas, São Paulo, Brazil.
Marcelo
0000-0002-9371-9975
M
G de Oliveira
Postgraduate Program in Morphofunctional Sciences, Department of Morphology, School of Medicine, Federal University of Ceará, Fortaleza, Ceará, Brazil.
Gerly A C
GA
Brito
D000287:Administration, Topical; D016301:Alveolar Bone Loss / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D000818:Animals; D004195:Disease Models, Animal; D005881:Gingiva / Q000187:drug effects / Q000378:metabolism; D065347:Hypromellose Derivatives / Q000008:administration & dosage*; D007249:Inflammation / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D053583:Interleukin-1beta / Q000378:metabolism; D008297:Male; D020030:Nitric Oxide Donors / Q000008:administration & dosage; D052247:Nitric Oxide Synthase Type II / Q000378:metabolism; D010510:Periodontal Diseases / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D051381:Rats; D017208:Rats, Wistar; D053246:Receptor Activator of Nuclear Factor-kappa B / Q000378:metabolism; D026422:S-Nitrosoglutathione / Q000008:administration & dosage*; D012996:Solutions; D000071681:Tartrate-Resistant Acid Phosphatase / Q000378:metabolism; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism
D053583:Interleukin-1beta; D020030:Nitric Oxide Donors; D053246:Receptor Activator of Nuclear Factor-kappa B; D012996:Solutions; D014409:Tumor Necrosis Factor-alpha; D065347:Hypromellose Derivatives; D026422:S-Nitrosoglutathione; D052247:Nitric Oxide Synthase Type II; C496318:Nos2 protein, rat; D000071681:Tartrate-Resistant Acid Phosphatase